Loading
An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment. ClinicalTrials.gov record last updated 2026-06-02: recruiting. Enrollment is planned at 30 participants. Primary completion is estimated at 2026-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/